Key result
Bisoprolol exhibits predictable pharmacokinetics with 90% absolute bioavailability, a 10-11 hour half-life, and balanced clearance independent of dose from 2.5 to.
Bisoprolol possesses optimized pharmacokinetic properties, including high bioavailability and balanced clearance, which contribute to its therapeutic reliability.
Answers are grounded in this paper and cite their sources.
May support dosing flexibility in mild organ impairment; leaves open prospective outcome trials in special populations.
Bisoprolol exhibits a high absolute bioavailability (90%) because of its nearly complete absorption (> 90%) and small first-pass effect (10%). Bioavailability is independent of food intake. A long plasma-elimination half-life (10-11 h) allows a once-a-day dose regimen. Because of the low plasma protein-binding (30%), kinetics are insensitive to protein-binding interactions. The balanced clearance (equieffective hepatic and renal clearance) renders the kinetics virtually insensitive to renal or hepatic insufficiency. Even in the case of complete failure of one clearance organ, the plasma elimination half-life of bisoprolol would only double. The metabolites that are inactive and do not accumulate are eliminated predominantly by the kidneys. There is no stereoselective metabolism. The metabolism of bisoprolol is insensitive to liver enzyme inhibition (cimetidine), and nearly insensitive to liver enzyme induction (rifampicin). The metabolism is independent of genetic oxidationpolymorphism (debrisoquine). The pharmacokinetics of bisoprolol are independent of the dose in the range from 2.5 to 100 mg. There is no age or sex dependency. Bisoprolol exhibits predictable pharmacokinetics with well-balanced properties leading to small intra- and interindividual variability of the plasma concentration time curves and pharmacokinetic parameters. Bisoprolol is the β-blocker with LADME(liberation, absorption, distribution, metabolism, and elimination)-optimized pharmacokinetics. This is a prerequisite for therapeutic reliability.
No takes yet. Share an insight, caveat, or question.
Dale B. Evans (1986) reported a review. Bisoprolol was evaluated. Bisoprolol exhibits predictable pharmacokinetics with 90% absolute bioavailability, a 10-11 hour half-life, and balanced clearance independent of dose from 2.5 to.
Synapse has enriched 10 related papers. Consider them for comparative context: